USE OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)

Abstract: Vascular endothelial growth factor (VEGF) is identified as having a role in regulating the phosphorylation state of cadherin-associated proteins p120 and p100 in endothelial cells. VEGF may therefore have a role in pathologies involving abnormal cell-cell junctions. Methods for visualising the phosphorylation effects of VEGF on p120 and p100 are provided. VEGF may be used to screen for agents which are also capable of affecting the phosphorylation state of p120 and/or p100, or for agents which interfere with VEGF-initiated signalling that regulates p120/p100 phosphorylation.

Description: USE OF VASCULARENDOTHELIAL GROWTH FACTOR (VEGF) The present invention relates inter alia to signalling transduction pathways and the regulation of cell-cell adhesion. Such regulation is important in a variety of pathological situations. It is known that epithelial and endothelial cells adhere to their neighbours through specific adhesion complexes [see Cell 1996 Feb 9;84(3):345-57. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Gumbiner BM]. In particular, the adherens junction is the site of calcium-dependent adhesion between these cells. The adherens junction is composed of single-pass transmembrane adhesion molecules called the cadhenns. Cadherins are calcium-dependent adhesion molecules that play a key role in initiating and maintaining intercellular contact. The classic cadherins are single-pass, transmembrane glycoproteins that interact homotypically with cadherins on neighbouring cells. Crucial for cadherin function is association via their cytoplasmic tail with a group of proteins termed catenins. Cadherin binds directly to β- or γ-catenin, proteins related to the Drosophila segment polarity gene product Armadillo, which then binds to α-catenin, a vinculin homologue, that links the complex to the actin-based cytoskeleton [see J Cell Biochem 1996 Jun 15;61(4):514- 23. Cadherin-catenin complex: protein interactions and their implications for cadherin function. Aberle H, Schwartz H, Kemler R]. pi 20, another catenin, was originally discovered as a Src substrate, tyrosine phosphorylation of which may be involved in cellular transformation [see Bioessays 1997 Oct;19(10):883-91. Tyrosine phosphorylation and cadherin/catenin function. Daniel JM, Reynolds AB]. It too is a member of the Armadillo family and was subsequently realised to be associated with cadherins in both epithelial and endothelial cells. A pl20 related protein plOO also exists, probably as a result of alternative splicing of the pl20 gene. More details in respect of plOO and pl20 can be found from WO95/13820, WO96/16170 and WO98/14186. The role of the adherens junction is to initiate and maintain cell-cell contact. Furthermore, the formation of other junctions such as the tight junction is critically dependent on the prior formation and maintenance of adherens junctions. Aberrant regulation of adherens junctions can result in metastasis, loss of contact inhibition and tissue oedema [see Pathol Res Pract 1996 Jul;192(7):694-707. Regulation of the invasion suppressor function of the cadherin/catenin complex. Vermeulen S, Van Marck V, Van Hoorde L, Van Roy F, Bracke M, Mareel M.] There is a fair amount of evidence that the cadherin/catenin complex is a target for signalling pathways. Of particular relevance to the present invention is that pi 20 and pi 00 are targets for a protein kinase C (PKC) activated signalling pathway (the PKC- pl20/pl00 pathway) in epithelial cells. In this case, protein kinase C activation resulted in decreased serine/threonine phosphorylation of pl20/pl00. Protein kinase C activation must cause pl20/pl20 dephosphorylation by pl20/pl00 kinase inhibition or activation of the corresponding phosphatase [J Biol Chem 1997 Dec 12;272(50):31894-901. Dephosphorylation of the cadherin-associated pl00/pl20 proteins in response to activation of protein kinase C in epithelial cells. Ratcliffe MJ, Rubin LL, Staddon JM]. The PKC-pl20/pl00 pathway is clearly present in endothelial cells, as revealed by the use of phorbol-12,13-dibutyrate, a pharmacological activator of PKC. Endothelial cells possess receptors for agents such as histamine and thrombin, known to be involved in the inflammatory response. It was also found that pl20/pl00 phosphorylation in endothelial cells is clearly regulated by these inflammatory agents (as described in WO 98/14186). According to a first aspect, the present invention provides the use of VEGF to screen for a substance capable of affecting the phosphorylation state of pi 20 and/or pi 00. The screen may be for a substance capable of blocking the dephosphorylation of pi 20 and/or plOO. The substance may affect the phosphorylation state of pl20 and/or plOO, e.g. by blocking the dephosphorylation of pl20 and/or plOO. The dephosphorylation may be from the phosphorylated serine and/or threonine residues present in pi 20 and/or pi 00. Preferably the screen is to identify a substance which is capable of affecting the phosphorylation state of pl20 and/or plOO. A method to screen for a substance capable of affecting the phosphorylation state of pi 20 and/or pi 00, comprising the use of VEGF, is also provided. In a second aspect, the present invention provides a substance identifiable by the use of a screen as set out in the first aspect. The substance may be identified by the ue of a screen as set out in the first aspect. Preferred features of the first aspect of the invention apply to the second aspect. In a third aspect, the present invention provides the use of VEGF to screen for a substance capable of interfering with a VEGF-initiated pathway regulating pl20/pl00 serine/threonine phosphorylation. The pathway may be the PKC-pl20/pl00 pathway. Preferably the screen is to identify an inhibitor and or a competitor and/or an activator of VEGF (in particular when the VEGF is involved in the pathway regulating pl20/pl00 serine/threonine phosphorylation). In a fourth aspect, the present invention provides an inhibitor and/or a competitor and or an activator of VEGF identifiable by a screen as set out in the third aspect. The inhibitor and or competitor and/or activator may be identified by the screen. Preferred features of the third aspect of the invention also apply to the fourth aspect. In a fifth aspect, the present invention provides a method to identify the phosphorylation state of pi 20 and/or pi 00 comprising identifying a mobility shift of these proteins as revealed by an immunoblotting procedure. The phosphorylation state of pl20 and/or plOO may be affected by VEGF. The method may be for the diagnosis of a disease, which disease may involve VEGF. The method may also be used in the evaluation of efficacy of a drug being used or tested to control a disease involving VEGF. In a sixth aspect, the present invention provides a method to identify the phosphorylation state of pi 20 and/or pi 00 comprising the use of an antibody specific for one or more of the phosphorylation sites on pl20 and/or plOO. The method may be for the diagnosis of a disease, which disease may involve VEGF. The method may also be used in the evaluation of efficacy of a drug being used or tested to control a disease involving VEGF. In a seventh aspect, the present invention provides a method to screen for a compound or other agent that interferes with a signalling pathway capable of being initiated by VEGF to regulate pl20/pl00 phosphorylation, comprising the identification of the phosphorylation state of pi 20 and/or pi 00, in the presence of the compound or the other agent, and optionally comparing the phosphorylation state with a standard. The identification of the phosphorylation state may be by monitoring a band shift of pi 20 and or pi 00. Preferably the screen identifies a compound or other agent that interferes with a signalling pathway capable of being initiated by VEGF. In an eighth aspect, the present invention provides a compound or other agent that interferes with a signalling pathway capable of being initiated by VEGF, identifiable by a method as described in the seventh aspect of the present invention. Preferred features of the seventh aspect also apply to the eighth aspect. The compound or agent may interefere with a signalling pathway that is initiated by VEGF. It may be identified by a method as set out in the seventh aspect. The present invention discloses that vascular endothelial growth factor (VEGF), a potent and important angiogenic factor, also known as vascular permeability factor [see Cancer J Sci Am 1998 Jul-Aug;4(4):209-17. New developments in angiogenesis: a major mechanism for tumor growth and target for therapy. Jones A, Harris AL; Thromb Haemost 1997 Jul;78(l):678-83. Angiogenesis in embryos and ischemic diseases. Breier G, Damert A, Plate KH, Risau W; Endocr Rev 1997 Feb;18(l):4-25. The biology of vascular endothelial growth factor. Ferrara N, Davis-Smyth T], also stimulates pi 20 and pi 00 dephosphorylation in endothelial cells. VEGFι 65 as well as other variants of VEGF may be used, such as amino acid sequence variants (muteins or polymorphic variants), a species of VEGF comprising additional residues, and any naturally occurring allelic and/or splice variants [Neufeld G et al, Cancer Metastasis Rev 1996 Jun 15(2) 153-8. "Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants"] The pi 20 and pi 00 dephosphorylation is revealed by SDS-PAGE and immunoblotting as a band-shift (also called mobility shift), hereafter referred to as the pl20/pl00 band shift (as shown in Example 1). The response is rapid and blocked by an inhibitor of the VEGF receptor tyrosine kinase. Therefore, the invention provides a simple method of visualizing phosphorylation effects triggered by VEGF on pl20/pl00. Regulation of pl20/pl00 phosphorylation, as adherens junction-associated proteins may turn out to be important in their regulation of cell-cell adhesion, angiogenesis and tissue oedema. VEGF and therefore pl20/pl00 serine/threonine phosphorylation may be important in pathologies involving cancer and hypoxia. VEGF is known to be an important angiogenic factor. Anti-angiogenic and therefore anti VEGF strategies are being considered as therapy for cancer and other hypoxic conditions such as retinopathy. VEGF is also a key regulator of vascular permeability in pathologies involving hypoxia. The ensuing oedema can contribute significantly to the morbidity and mortality of patients. Regulation of cadherin function may be crucial to the mode of action of VEGF. The present invention reports on a method to visualize phosphorylation effects of VEGF on the cadherin-associated proteins pi 20 and plOO. The invention could be useful in diagnosis and screening for agents interfering with VEGF initiated signalling that regulates pl20/pl00 phosphorylation. Various aspects of the present invention will now be considered in order that its full scope can be appreciated. Diagnostics Uses The pl20/pl00 band shift can be used to diagnose biopsy samples to report on the state of pl20/pl00 phosphorylation. Such diagnosis may be important in making therapeutic decisions or reporting on the efficacy of therapeutic drugs. Screening ses The pl20/pl00 band shift could be used as a method to screen for compounds which interfere with VEGF-initiated signalling pathways regulating pl20/pl00 phosphorylation. Identification of specific phosphorylated residues within pi 20 or pi 00 affected in response to VEGF could lead to the establishment of phosphatase or kinase assays and the screening of compounds affecting such enzymes. Appropriate fusion proteins or peptides could be used as substrates. Uses in Raising or Selecting Antibodies A further use of the present invention is in raising or selecting antibodies. Antibodies recognizing pl20 or pi 00 in phosphorylated or dephosphorylated forms could be raised and used as described under Diagnostic Uses and Screening Uses. Antibodies could be used in immunoblots, ELIS As or for irnmunocytochemistry of cultured cells or pathology specimens. Figures The present invention will now be described by way of example only with reference to the accompanying figures; wherein: Figure 1 shows an immunoblot of pi 20 and pi 00 and the effect of VEGF treatment, as described in Experiment 1 below; Figure 2 shows an immunoblot of pl20 and plOO, which indicates that VEGF acts rapidly, as described in Experiment 2 below; Figure 3 shows an immunoblot of pi 20 and pi 00, which indicates that VEGF acts potently, as described in Experiment 2 below; Figure 4 shows an immunoblot of pi 20 and pi 00, which indicates that VEGF acts via VEGFR-2 (KDR/Flk-1), as described in Experiment 3 below; Figure 5 shows an immunoblot, which indicates that the [ 32 P]phosphate incorporation into pi 20 and pi 00 and the results of probing the filter with antibody recognizing pi 20 and pi 00, as described in Experiment 4 below; Figure 6 shows an immunoblot, which indicates that VEGF induces dephosphorylation of pi 20 and pi 00 at similar sites, as described in Experiment 5 below; Figure 7 shows an immunoblot, which indicates that VEGF stimulates serine/threonine dephosphorylation of pi 20 and pi 00 and does not affect tyrosine phosphorylation, as described in Experiment 6 below; and Figure 8 shows that increased phosphotyrosine in response to VEGF does not colocalize with adherens junction associated protein, as described in Experiments 6 and 7 below. Methods Chemicals and Reagents VEGFi 65 was from PeproTech. Placenta growth factor (P/GF) was from R & D Systems. Phorbol-12,13-dibutyrate (PDB) was from Calbiochem-Novabiochem. Histamine was from Sigma Chemical Co. SU5416 was prepared by Tsukuba Research Laboratories, Eisai Co., Tsukuba, Japan. Collagen (Vitrogen 100) was obtained from Imperial Laboratories (Europe). [ 32 P]Phosphate (10 mCi/ml, carrier free) was from ICN-Flow Laboratories. Staphyloccocus aureus strain V8 protease (P-6306) was from Sigma. Antibodies Mouse monoclonal antibodies recognising VE-cadherin (cadherin-5), N-cadherin, both pl20 and plOO, β-catenin and phosphotyrosine (PY20), .and the rabbit polyclonal anti- phosphotyrosine, were from Transduction Laboratories. Peptide-directed antibodies recognizing - and γ-catenin were provided by Kurt Herrenknecht (Eisai London Research Laboratories). Rabbit polyclonal antibody recognizing the activated forms (phosphoThr o 2 /phosphoTyr 2 o 4 ) of p42 and p44 MAP kinase was from New England BioLabs. Mouse monoclonal anti-vinculin (VIN-11-5) was from Sigma. Antibodies recognizing ZO-1 and CD31 were from Zymed and Dako, respectively. HRP- conjugated secondary antibodies were from Amersham. Both fluorochrome- conjugated (Cy3 or fluorescein) secondary antibodies and the rabbit anti-mouse IgG were from Jackson ImmunoResearch Labs. Cells and Treatments Human umbilical vein endothelial cells (HUVEC), pooled donors, were from BioWhittaker and cultured in EGM on collagen-coated plastic (Falcon) according to the supplier's instructions. The cells were cultured in medium in the presence of 100 U/ml penicillin and 100 μg/ml streptomycin at 37°C in humidified air containing 10% CO 2 . Routinely, stocks were maintained in 75 cm 2 flasks and split at a 1 :3 ratio when almost confluent. For experimental use, cells were seeded in appropriate plasticware such that confluence was established within 2-3 days and the cells were usually used 5-6 days after seeding. Prior to experimental use, confluent monolayers of cells were equilibrated in fresh medium for at least 2 hours prior to the start of the experiment. Compounds and agents that were only soluble in Me 2 SO were added to the culture medium of the cells in an equal volume of CO 2 - and temperature-equilibrated medium containing twice the finally required concentration of compound. The final concentration of Me SO did not exceed 0.1% (v/v). Aqueous soluble agents were added at a 1:100 dilution directly to the cultures. In all cases, appropriate vehicle controls were performed and found to have no effect. [ 32 P]Phosphate labelling was performed using Puck's Saline A (P-2917; Sigma) supplemented with 10 mM Hepes (Gibco), 2 mM glutamine (Gibco), 1 mM CaCl , 1 mM MgSO 4 and 0.2% (v/v) foetal calf serum. Cultures were rinsed twice with medium and then incubated with the same medium containing 100 μCi/ml of [ Pjphosphate. Labelling was for 2 hours at 37°C in humidified air with ambient CO 2 . Protein Analysis Whole cell lysates were prepared by aspiration of culture medium and immediately replacing it with boiling hot Laemmli sample buffer (Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685) supplemented with 5 mM EDTA.Na^ The samples were collected and heated at 100°C for 5 minutes. Proteins were resolved by gel electrophoresis using 8% acrylamide slab gels (Hoefer SE 600 system, 16 cm) and the buffers described (Laemmli, 1970, loc cit). Gels were run overnight at 55 V. The gels were then equilibrated for 30 minutes in buffer at 4°C containing 48 mM Tris, 39 mM glycine, 0.03%) SDS (w/v) and 20% methanol (v/v), and electrotransferred to nitrocellulose filters (Hybond ECL, Amersham) at 4°C. After Ponceau S staining, the filters were blocked in PBS containing 1% (w/v) BSA and 0.05% (v/v) Tween-20. The filters were then incubated with primary antibody, rinsed and immunoreactive bands were detected using appropriate HRP-conjugated secondary antibody and chemiluminescence (ECL, Amersham). For analysis of the cadherin and its association with catenins, extraction and immunoprecipitations were performed at 4°C. Cultures were briefly rinsed with ice- cold PBS and then lysed in TX buffer (1% (v/v) Triton X-100, 25 mM Hepes, 2 mM EDTA, 0.1 M NaCl, 25 mM NaF, 1 mM vanadate, pH 7.6 (adjusted with NaOH), 1 mM PMSF, 10 μg/ml soybean trypsin inhibitor, 0.1 U/ml α 2 -macroglobulin, 10 μg/ml leupeptin). The cells were extracted into lysis buffer for 10-15 minutes and then collected after scraping the dish. The lysates were centrifuged at 14,000 x g for 20 minutes. The supernatant was precleared with protein A-Sepharose (Pharmacia) for 1 hour and then incubated with primary antibody for 1 hour followed by a further 1 hour with protein A-Sepharose together with rabbit anti-mouse antibodies. After five washes in lysis buffer, immune complexes were dissociated by addition of Laemmli sample buffer followed by heating at 100°C for 5 minutes. Protein analysis was by SDS-PAGE and immunoblotting as described above. For pl20/pl00-specific and phosphotyrosine (PY20) protein immunoprecipitations, the cells were lysed in boiling SDSSB (1% SDS, 25 mM Hepes, 2 mM EDTA, 0.1 M NaCl, 25 mM NaF, 1 mM vanadate, pH 7.6). The lysate was then collected, heated at 100°C for 5 minutes, cooled and diluted with four volumes of ice-cold TX buffer that contained 2.9% instead of 1% Triton X-100. Immunoprecipitation was performed as described for TX buffer extractions. For phosphorylation analysis, cultures of HUNECs were labelled with [ 32 P]orthophosphate. After appropriate treatment, the cultures were lysed in boiling SDSSB and immunoprecipitated with the anti-pl20/pl00 antibody as described. For quantitation of [ 32 P]phosphate:protein, each immunoprecipitation was from protein extracted from ~10 cm 2 of confluent culture. For the phosphoaminoacid analysis and Cleveland maps, protein from -60 cm of confluent cells was used per immunoprecipitation. After separation by SDS-PAGE, for quantitation of [ 32 P]phosphate .and pl20/pl00, protein was transferred to nitrocellulose and [ 32 P]phosphate incorporated into pl20/pl00 was detected by autoradiography. The filter was then probed with antibody recognizing pi 20 and pi 00 to quantitate protein levels, as described. For both the autoradiography and luminography, preflashed film was used. For phosphoamino acid analysis, after separation by SDS-PAGE, proteins were transferred to Immobilon P (Millipore). The area of filter containing pl20 or pi 00 was detected by autoradiography, excised, and protein was acid hydro lysed to release phosphoaminoacids. These were then separated in two dimensions by high voltage electrophoresis at pH 1.9 and pH 3.5 and detected by autoradiography (Boyle et al., 1991). For proteolytic mapping (Cleveland, D. W., Fischer, S. G., Kirschner, M. W. and Laemmli, U. K. (1977) Peptide mapping by limited proteolysis in sodium dodecyl sulfate and analysis by gel electrophoresis. J Biol. Chem. 252, 1102-1106), the immunoprecipitated proteins were resolved by SDS-PAGE, briefly fixed and detected by autoradiography of the dried gels. Regions of gel containing pl20 and pi 00 were excised. These gel slices were then rehydrated in TSE buffer (0.5 M Tris/HCl, pH 6.8; 0.1% SDS; 1 mM EDTA.Na-,) containing 20% glycerol, inserted into the well of the stacking gel containing 1 mM EDTA.Na 4 and overlaid with TSE buffer containing 10% > glycerol and 100 ng of V8 protease. Following overnight electrophoresis at 60 V, the 15%) gel, which again contained EDTA, was fixed, dried and autoradiographed at -80°C. Immunocytochemistry Confluent monolayers of cells were fixed at room temperature for 15 minutes in 3% paraformaldehyde made up in PBS. Fixed cells were rinsed and then permeabihzed by incubation with 0.5% Triton X-100 in PBS for 30 minutes. All antibodies were diluted in PBS containing 10% FCS, 0.1 M lysine, 0.3% Triton-X-100 and 0.02% azide. Incubation with antibody recognizing junction-associated protein was at 4°C overnight followed by incubation with mouse or rabbit anti-phosphotyrosine antibody for 2 hours at room temperature. Secondary antibodies recognizing mouse and rabbit IgG conjugated to Cy3 or fluorescein, respectively, were applied together for 1 hour at room temperature. After rinsing, the samples were mounted under Citifluor and viewed with epifluorescence on a Nikon Eclipse E800 microscope. Photographs were taken using Kodak T-MAX film (400 ASA). Experiment 1 Human umbilical vein endothelial cells were incubated in the absence (Control - lane labelled C) or presence of 2.6 nM VEGF for 5 minutes. Incubations were performed in triplicate and analyzed in parallel. The cells were extracted in Laemmli sample buffer and proteins were resolved by SDS-PAGE. Following transfer to nitrocellulose, the filters were probed with antibody recognizing pl20 and plOO (see Fig. 1A). pl20 (migration indicated by the open circle) and pi 00 (migration indicated by the closed circle) from untreated cells migrate as broad bands. Those from VEGF treated cells (lane labelled V) migrate as faster, tighter bands. Other experiments have shown that this is due to the loss of phosphate from the protein on serine and threonine residues. For comparative purposes, the cells were also incubated with either 10 μM histamine (lane labelled H) or 200 nM phorbol 12,13 dibutyrate (lane labelled P) for 5 minutes and analyzed in parallel. To reveal other changes in VEGF-stimulated signalling processes, the filters were also probed with an antibody recognizing the activated forms of p42 and p44 MAP kinase. VEGF clearly stimulated an increase in the amount of phosphorylated MAP kinase in parallel with its ability to affect pl20/pl00 migration (Fig. IB). Histamine (H), likewise, increased the amounts of phospho-MAP kinases but the phorbol ester (P) was without effect (Fig. IB). All lanes received equal amounts of protein as determined by Ponceau S staining of the filters and verification by reprobing with antibody recognizing β-catenin (results not shown). Experiment 2 The kinetics and potency of the VEGF effect were examined. See Figure 2. Confluent monolayers of HUNECs were incubated in the absence (-) or presence (+) of 2.6 nM (100 ng/ml) VEGF for the times indicated. Cell extracts were prepared and pl20 (O ) and plOO (•) were detected by immunoblotting following SDS-PAGE, Figure 2, Panel A. The same filter was also probed with the antibody recognizing the activated forms of p42 and p44 MAP kinase (arrowheads), Figure 2, Panel B. Equal loading of lanes was verified as in Fig. 1. VEGF acted very rapidly to trigger the increase in mobility of pi 20 and pi 00, effects were observed within 2 minutes and sustained for up to 30 minutes (Fig. 2A). After 60 minutes of incubation, the effect was less apparent (Fig. 2A). The kinetics paralleled those of the increase in amount of activated MAP kinase (Fig. 2B). Confluent monolayers of HUVECs were incubated for 5 minutes in the absence (-) or presence (+) of the indicated concentrations of VEGF. Cell extracts were prepared and pl20 (O ) and plOO (•) were detected by immunoblotting following SDS-PAGE, Figure 3, Panel A. The same filter was also probed with the antibody recognizing the activated forms of p42 and p44 MAP kinase (arrowheads), Figure 3, Panel B. Equal loading lanes was verified as in Fig. 1. VEGF was also very potent at affecting pl20/pl00 mobility, effects were observed with concentrations as low as 0.1 nM (Fig. 3 A). The sensitivity of the increase in amount of activated MAP kinase paralleled that of the increase in pl20/pl00 mobility (Fig. 3B). Experiment 3 VEGF is known to bind to two receptors, VEGFR-1 and VEGFR-2. To determine which receptor(s) were responsible for the pl20/pl00 shift, the effects of placenta derived growth factor (P/GF), a VEGFR-1 -specific ligand, were examined. Confluent monolayers of HUVECs were incubated for 5 minutes in the absence (lane labelled C) or presence of P/GF at 100 (P/GF 100 ) or 1000 ng/ml (P/GFiooo). In parallel, the cells were treated with either 10 μM histamine (His) or 2.6 nM (100 ng/ml) VEGF. In another experiment, the cells were preincubated for 30 minutes in the absence (-) or presence(+) of 5 μM of the VEGFR-2 inhibitor SU5416. The cells were then treated for 5 minutes with either 2.6 nM VEGF (V) or 10 μM histamine (H). In all cases, cell extracts were prepared and pl20 (O ) and plOO (•) were detected by immunoblotting following SDS-PAGE, Figures 4A and 4C. The same filter was also probed with antibody recognizing the activated forms of p42 and p44 MAP kinase (arrowheads), Figures 4B and 4D. Equal loading of lanes was verified as in Fig. 1. Even at concentrations up to 1000 ng/ml, P/GF failed to stimulate a mobility shift in pl20/pl00 (Fig. 4A) and also did not lead to activation of MAP kinase (Fig. 4B), whereas appropriate positive controls (VEGF, histamine) carried out in parallel were effective. These observations suggest that VEGF acted via VEGFR-2. This was corroborated by the finding that the VEGFR-2 specific inhibitor SU5416 (Sun, L., Tran, N., Tang, F., App, H., Hirth, P., McMahon, G. and Tang, C. (1998) Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectively toward particular receptor kinases. J. Med. Chem. 41, 2588-2603. Fong, T. A. T., Shawver, L. K., Sun, L., Tang, C, App, H., Powell, j. P., Kim, Y. H., Schreck, R., Wang, X., Risau, W., Ullrich, A., Hirth, K. P. and McMahon, G. (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59 99-106) blocked the ability of VEGF to stimulate an increase in pl20/pl00 mobility (Fig. 4C) and activation of MAP kinase (Fig. 4D). In contrast, SU5416 did not block the ability of histamine to stimulate a mobility shift in pl20/pl00 or to activate MAP kinase (Figs. 4C,D), indicating selectivity in its mode of action. Experiment 4 To explore the basis of the increase in mobility of pl20/pl00 stimulated by VEGF, phosphorylation analysis was performed. The cells were metabolically labelled with [ 32 P]phosphate, stimulated as required, lysed in buffer designed to preserve the phosphorylation state of proteins, immunoprecipitated with antibody recognizing pi 20 and pi 00 and then analyzed by SDS-PAGE, autoradiography and immunoblotting. This approach allows quantitation of phosphate per amount of protein. Confluent monolayers of HUVECs were metabolically labelled with [ 32 P]phosphate. The cells were then treated for 5 minutes with vehicle (lanes labelled C), 10 μM histamine (lanes labelled H), 200 nM PDB (lanes labelled P) or 2.6 nM VEGF (lanes labelled V). Following lysis in TDS buffer, pl20 and plOO were immunoprecipitated, resolved by SDS-PAGE and transferred to nitrocellulose. An autoradiogram of the filter was taken to detect [ 32 P]phosphate incorporation into pl20 (O ) and plOO (•), Figure 5 A, and the filter was then probed with antibody recognizing pi 20 and pi 00 to detect protein (Figure 5B). Autoradiography was for 40 hours at -80°C and the ECL exposure was taken in 1 minute. Band densities in the autoradiogram and luminogram were quantitated by densitometry and the [ Pjphosphate incorporation normalized to protein is expressed in Figure 5C. As a control, an aliquot of the supernatant from the immunoprecipitations was analyzed by SDS-PAGE and autoradiography. The result (not shown) indicated that there were no general effects on labelling of the multitude of proteins in this fraction. pi 20 and pi 00 were detected as phosphoproteins in control cells and the [32P]phosphate:protein was determined (Fig. 5 A). After incubation of the cells with VEGF, the autoradiogram showed that the [ 32 P]phosphate signal was less and the film density was similar to that of pl20/pl00 from control cells (Fig. 5 A). Examination of the immunoblot of the same filter (Fig. 5B) showed that VEGF caused an increase in pl20/pl00 mobility and an increase in film density of the ECL signal. Quantitation by densitometry revealed that VEGF stimulated dephosphorylation of pl20 and plOO (Fig. 5C), and that this dephosphorylation was similar in magnitude to that elicited by histamine or PDB (Figs. 5A-C). In response to VEGF, histamine and PDB, pl20/pl00 were dephosphorylated resulting in increased electrophoretic mobility. The autoradiogram showed less of a signal whereas the immunoblot showed an increased intensity as the protein was concentrated during electrophoresis. In all cases, the supernatants from the immunoprecipitations were analyzed to confirm that there were no general effects on the phosphorylation of the many proteins present in these fractions (result not shown). Experiment 5 Phosphorylation sites within pl20/pl00 were analyzed. See Figure 6. HUVECs were metabolically labelled with [ 32 P]phosphate, stimulated as required and phosphorylation site analysis was performed by Cleveland mapping, a procedure involving limited proteolytic digestion. Confluent monolayers of HUVECs were metabolically labelled with [ 32 P]phosphate. The cells were then treated for 5 minutes with vehicle (C), 10 μM histamine (H), 200 nM PDB (P) or 2.6 nM VEGF (V). Following lysis in TDS buffer, pl20 and plOO were immunoprecipitated and resolved by SDS-PAGE. The gel was briefly fixed and an autoradiogram taken to localize bands conesponding to pi 20 and pi 00. These were excised from the gel partially digested with V8 protease and the digestion products were analyzed by SDS-PAGE. The labelling of digestion products was detected again by autoradiography. It was confirmed by immunoblotting that the amounts of pi 20 and pi 00 in the initial immunoprecipitates were equal. For both pi 20 and pi 00, two major cleavage products at 30 kDa and 17 kDa were observed when protein was extracted from control cells (Fig. 6). After VEGF stimulation, phosphate incorporation into both of these fragments was substantially decreased (Fig. 6). After incubation of the cells with histamine or phorbol dibutyrate, similar effects on the pi 20 and pi 00 maps were observed (Fig. 6) suggesting that these different stimuli affect pi 20 and pi 00 phosphorylation at similar sites. Experiment 6 Two types of experiment were carried out to investigate which amino acids were phosphorylated. Confluent monolayers of HUVECs were incubated for 5 minutes in the absence (C) or presence of either lOμM histamine (H) or 2.6nM VEGF. Some cells were treated for 15 minutes with lOOμM of the broad-spectrum tyrosine phosphatase inhibitor, pervanadate. Lysates of the cells were prepared by immediate extraction into a boiling solution of an SDS-based buffer containing kinase and phosphatase inhibitors, as described above. As positive controls for this experiment, the extracts were analyzed for a pl20/pl00 shift, activation of MAP kinase or content of β-catenin. As expected, VEGF and histamine produced effects on pl20/pl00 (Fig. 7A) and MAP kinase (Fig. 7B). Pervanadate (Pv) did not affect the mobility of pl20/pl00 (Fig. 7A) but did lead to activation of MAP kinase (Fig. 7B). The levels of βcatenin were found to be similar in all extracts (Fig. 7C). These extracts were then immunoprecipitated with antiphosphotyrosine antibody PY20 and analyzed by immunoblotting with PY20 (Fig. 7D). In the controls, several major bands were observed. The open squares indicate the migration of bands conesponding, in order of decreasing size, to VEGFR-2, FAK and paxillin. The PY20 immunoprecipitates were also probed with antibody recognizing β-catenin (open anow head), Panel E, pl20 (O ) and plOO (•), Panel F. The same PY20 immunoprecipitates were probed with antibodies recognizing β- catenin (Fig. 7E) or pl20/pl00 (Fig. 7F). Only after treatment with pervanadate were β-catenin and pl20/pl00 detected in the phosphotyrosine immunoprecipitates. A ten- times overexposure of the filters did not reveal any hint of β-catenin or pl20/pl00 in the phosphotyrosine immunoprecipitates in response to VEGF or histamine (results not shown). Therefore, even though the PY20 immunoprecipitates revealed tyrosine phosphorylation of proteins already reported to be tyrosine phosphorylated in response to VEGF and histamine, these same immunoprecipitates did not contain β-catenin or pl20/pl00. Phosphoaminoacid analysis of pl20/pl00 was also performed. In control HUVECs, pi 20 and pi 00 were phosphorylated on mainly serine and, to a lesser extent, threonine residues (Fig. 7G). Confluent monolayers of HUVECs were metabolically labelled with [ 32 P]phosphate and received either vehicle (C), 10 μM histamine (H), 200 nM PDB (P) or 2.6 nM VEGF (V) for 5 minutes. Following lysis in TDS buffer and immunoprecipitation, phosphoaminoacid analysis of pi 20 and pi 00 was performed as described under Materials and Methods. The migration of phosphoaminoacid standards (PAAs) is also shown (S, phosphoserine; T, phosphothreonine; Y, phosphotyrosine). No phosphotyrosine was detected. After stimulation with VEGF, again phosphotyrosine was not detected but the amount of phosphoserine and phosphothreonine was decreased. Similar results were obtained after histamine and PDB treatment (Fig. 7G; previous experiments (Ratcliffe, M. J., Smales, C. S. and Staddon, J. M. (1999) Dephosphorylation of the catenins pi 20 and pi 00 in endothelial cells in response to inflammatory stimuli. Biochem. J. 338, 471-478) were done with EA.hy926 cells). These observations indicated that pl20 and plOO were dephosphorylated on serine and threonine residues in response to the various treatments. Increased phosphotyrosine in response to VEGF does not colocalize with adherens junction associated protein. HUVECs were either treated with vehicle (Control) or 2.6 nM VEGF. After 5 minutes, the cells were fixed and then stained. In parallel, cells were also extracted and analyzed for pl20/pl00 by immunoblotting to confirm that VEGF had in fact stimulated a pl20/pl00 shift. Panel A shows the results of colabelling with mouse antibody recognizing β-catenin and rabbit antibody recognizing phosphotyrosine (pY). The localization of β-catenin was not affected by VEGF treatment. Although VEGF resulted in alteration of phosphotyrosine staining, this did not colocalize with the staining of β-catenin, which had a very distinctive fine structure. Panel B shows the results of colabelling with mouse antibody recognizing vinculin and rabbit antibody recognizing phosphotyrosine (pY). VEGF treatment resulted in the appearance of vinculin-positive striations close to regions of cell-cell contact; these striations colabelled with phosphotyrosine antibody. In all cases, it was confirmed that the phosphotyrosine staining was competed by phosphotyrosine but not by phosphoserine or phosphothreonine. All images were from similarly timed exposures. Bar, 20 μm. In control cells, protein phosphorylated on tyrosine was detected as striations within the cells (Figs. 8A,B). Following VEGF treatment, these striations increased and the cells could be outlined (Figs. 8A,B). Some of the phosphotyrosine in both the control and VEGF -treated cells colocalized with vinculin (Fig. 8B) but not β-catenin, which had a very distinctive fine structure (Fig. 8 A). These data agree with the immunoprecipitation analysis (Fig. 7D) where focal contact protein tyrosine phosphorylation was increased in response to VEGF but that of catenins, including β-catenin, was not. Similar experiments where the cells were colabelled with phosphotyrosine antibody and antibody recognizing either pi 20, CD31 or ZO-1, also failed to reveal colocalization with these other junctional proteins after addition of VEGF (results not shown). Experiment 7 Cadherins associate via their cytoplasmic tail with the catenins, including pi 20 and pi 00. To test if VEGF treatment resulted in altered association of catenins with cadherins in endothelial cells, the cells were lysed under detergent conditions designed to preserve association of the complex. Lysates from control or VEGF-stimulated (2.6 nM, 5 minutes) cells were immunoprecipitated with antibodies recognizing both pi 20 and pi 00 or β-catenin. The immunoprecipitates were analyzed by immunoblotting for the content of VE-cadherin, N-cadherin, α, β and γ catenin, pi 20 and pi 00. VEGF treatment, although increasing the electrophoretic mobility of pi 20 and pi 00, had no effect on association of any members of the complex (results not shown). Furthermore, immunocytochemical analysis also did not reveal any apparent effects on localization of β-catenin (Fig. 8) or pl20/pl00 (result not shown) to adherens junctions following VEGF treatment.

Claims: CLAIMS 1. The use of VEGF to screen for a substance capable of affecting the phosphorylation state of pi 20 and/or pi 00. 2. The use of VEGF, as claimed in claim 1, wherein the screen is for a substance capable of blocking the dephosphorylation of pl20 and or plOO. 3. The use as claimed in claim 2, wherein the dephosphorylation is from the phosphorylated serine and/or threonine residues present in p 120 and/or p 100. 4. The use of a screen, as defined in any one of claims 1 to 3, to identify a substance which is capable of affecting the phosphorylation state of pl20 and/or plOO. 5. A substance identifiable by the use of a screen, as claimed in claim 4. 6. The use of VEGF to screen for a substance capable of interfering with a VEGF- initiated pathway regulating pl20/pl00 serine/threonine phosphorylation. 7. The use of VEGF, as claimed in claim 6, wherein the pathway is the PKC- pl20/p 100 pathway. 8. The use of VEGF, as claimed in claim 6 or claim 7, wherein the screen is to identify an inhibitor and/or a competitor and/or an activator of VEGF. 9. An inhibitor and or a competitor and/or an activator of VEGF identifiable by a screen as defined in claim 8. 10. A method to identify the phosphorylation state of pi 20 and/or pi 00 comprising identifying a band shift of these proteins as revealed by an immunoblotting procedure. 11. A method as claimed in claim 10 wherein the phosphorylation state of pi 20 and/or pi 00 is affected by VEGF. 12. A method to identify the phosphorylation state of pi 20 and/or pi 00 comprising the use of an antibody specific for one or more of the phosphorylation sites on pi 20 and/or pi 00. 13. A method, as claimed in any one of claims 10 to 12, in the diagnosis of a disease. 14. A method, as claimed in claim 13, wherein the disease involves VEGF. 15. A method, as claimed in any one of claims 10 to 14, in the evaluation of efficacy of a drug being used or tested to control diseases involving VEGF. 16. A method to screen for a compound or other agent that interferes with a signalling pathway capable of being initiated by VEGF to regulate pl20/pl00 phosphorylation comprising the identification of the phosphorylation state of pl20 and/or pi 00, in the presence of the compound or the other agent, and optionally comparing the phosphorylation state with a standard. 17. A method as claimed in claim 16, wherein the identification of the phosphorylation state is by monitoring a band shift of pi 20 and/or pi 00. 18. A method as claimed in claim 16 or claim 17, wherein the screen identifies a compound or other agent that interferes with a signalling pathway capable of being initiated by VEGF. 19. A compound or other agent that interferes with a signalling pathway capable of being initiated by VEGF, identifiable by a method as claimed in claim 18.

Inventors: MORGAN MARY LOUISE, STADDON JAMES MICHAEL, MORGAN, MARY, LOUISE, STADDON, JAMES, MICHAEL
Applicants: EISAI LONDON RES LAB LTD, MORGAN MARY LOUISE, STADDON JAMES MICHAEL, EISAI LONDON RESEARCH LABORATORIES LIMITED, MORGAN, MARY, LOUISE, STADDON, JAMES, MICHAEL
Application year: 1999
Main classification: G01N33
IPC codes: A61K45, A61P35, A61P37, G01N33